Yin et al. developed a series of CDK4/6i’s and identified a substance termed “compound 11” with the potential to inhibit CDK4/Cyclin D1 and CDK6/Cyclin D3 activity as well suppressing tumor p-RB1 at doses far below the FDA-approved CDKi’s [110]. Here, RB1 is linked to neoplasm.